Key Highlights
- Pulmonx and American Lung Association collaborate to empower severe COPD/emphysema patients.
- Launch of patient stories in EACH BREATH blog in November 2024.
- “Ask the Expert” session with a leading pulmonologist in January 2025 for community Q&A.
- Zephyr Valves recognized as a minimally invasive therapy for severe COPD by global treatment guidelines.
Source: Business Wire
Notable Quotes
- “We are excited to continue our partnership with the American Lung Association and together build awareness about the life-changing benefits of the Zephyr Valve therapy.” — Steve Williamson, CEO at Pulmonx
- “A COPD diagnosis can be devastating, but thankfully there are treatment options available to help improve the lives of people living with this disease.” — Deb Brown, Chief Mission Officer at American Lung Association
SoHC's Take
The expanded partnership between Pulmonx and the American Lung Association addresses the critical need for patient and clinician education on innovative COPD treatments. With COPD as the third leading cause of death worldwide, these initiatives could significantly improve awareness and adoption of therapies like the Zephyr Endobronchial Valve, enhancing quality of life for those affected. Pulmonx’s commitment to empowering patients with cutting-edge solutions solidifies its role as a leader in tackling severe lung diseases.
